682
Views
113
CrossRef citations to date
0
Altmetric
Original article: Clinical

Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

, , , , , & show all
Pages 1721-1727 | Received 21 Apr 2007, Accepted 06 Jul 2007, Published online: 01 Jul 2009

References

  • Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7: 1630–1636
  • Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
  • Horning S J, Hoppe R T, Breslin S, Bartlett N L, Brown B W, Rosenberg S A, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–637
  • Juweid M E. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. American Society of Hematology Education Program Book. American Society of Hematology, Washington, DC 2006; 259–265
  • Canellos G P. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931–933
  • Surbone A, Longo D L, DeVita V T, Jr, Ihde D C, Duffey P L, Jaffe E S, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832–1837
  • Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classic computed tomography scan imaging. Blood 1999; 94: 429–433
  • Juweid E M, Wiseman G A, Vose J M, Ritchie J M, Meuda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
  • Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
  • Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol 2004; 22: 1–4
  • Aleman B M, Raemaekers J M, Tirelli U, Bartolous R, van't Veer M B, Lybeert M L, et al. European Organization for Research and Treatment of Cancer Lymphoma Group: involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396–2406
  • Ferme C, Sebban C, Hennequin C, Divine M, Lederlin P, Gabane J, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomas de l'Adulte H89 trial. Blood 2000; 95: 2246–2252
  • Laskar S, Gupta T, Vimal S, Muckaden M A, Saikia T K, Pai K S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J Clin Oncol 2004; 22: 62–68
  • Aleman B M, van den Belt-Dusebout A W, Klokman W J, van't Veer M B, Bartelink H, van Leeuwen F E, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431–3439
  • Isasi C R, Lu P, Blaufox M D. A metaanalysis of 18 F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104: 1066–1074
  • Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007; 25: 571–578
  • Specht L. The role of PET in staging and response assessment in patients with Hodgkin's lymphoma. Hematology Education (The Education Program for the Annual Congress of the European Hematology Association). European Hematology Association, Vienna 2007; 60–63
  • Lavely W C, Delbeke D, Greer J P, Morgan D S, Byrne D W, Price R R, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin's and non-Hodgkin's lymphoma after first-line chemotherapy. Int J Radiot Oncol Biol Phyo 2003; 57: 307–315

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.